Global Obsessive-Compulsive Disorder Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Obsessive-Compulsive Disorder treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Addex Therapeutics Ltd, Amorsa Therapeutics Inc, Biohaven Pharmaceutical Holding Company Ltd, Omeros Corporation, Phytecs and others.
A Significant contribution to the Obsessive-Compulsive Disorder pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Obsessive-Compulsive Disorder pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Obsessive-Compulsive Disorder condition and increased access to investments is encouraging growth of Obsessive-Compulsive Disorder drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Obsessive-Compulsive Disorder drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Obsessive-Compulsive Disorder therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Obsessive-Compulsive Disorder pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Obsessive-Compulsive Disorder. Further, orphan drug status, fast track designation, grants awarded and other special status for Obsessive-Compulsive Disorder pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Obsessive-Compulsive Disorder pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Obsessive-Compulsive Disorder Pipeline candidates-
A Significant contribution to the Obsessive-Compulsive Disorder pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Obsessive-Compulsive Disorder pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Obsessive-Compulsive Disorder condition and increased access to investments is encouraging growth of Obsessive-Compulsive Disorder drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Obsessive-Compulsive Disorder drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Obsessive-Compulsive Disorder therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Obsessive-Compulsive Disorder pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Obsessive-Compulsive Disorder. Further, orphan drug status, fast track designation, grants awarded and other special status for Obsessive-Compulsive Disorder pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Obsessive-Compulsive Disorder pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Obsessive-Compulsive Disorder Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Obsessive-Compulsive Disorder drugs
- Late phase: Phase 3 and in-approval Obsessive-Compulsive Disorder drugs
- Company overview
- Snapshot
- Obsessive-Compulsive Disorder therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Obsessive-Compulsive Disorder- Disease Overview
2.2 Obsessive-Compulsive Disorder- Pipeline Snapshot
2.3 Obsessive-Compulsive Disorder- Pipeline Drugs by Phase
2.4 Obsessive-Compulsive Disorder- Pipeline Drugs by Company
2.5 Obsessive-Compulsive Disorder- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Addex Therapeutics Ltd Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.2 Amorsa Therapeutics Inc Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.3 Biohaven Pharmaceutical Holding Company Ltd Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.4 Omeros Corporation Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.5 Phytecs Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.6 Rugen Therapeutics Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.7 Seropeutics LLC Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Obsessive-Compulsive Disorder- Phase 1 Drug Details
4.2 Obsessive-Compulsive Disorder- Phase 1 Drug Overview
4.3 Obsessive-Compulsive Disorder- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Obsessive-Compulsive Disorder- Phase 2 Drug Details
5.2 Obsessive-Compulsive Disorder- Phase 2 Drug Overview
5.3 Obsessive-Compulsive Disorder- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Obsessive-Compulsive Disorder- Phase 3 Drug Details
6.2 Obsessive-Compulsive Disorder- Phase 3 Drug Overview
6.3 Obsessive-Compulsive Disorder- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Obsessive-Compulsive Disorder- Pre-clinical Phase Drug Details
7.2 Obsessive-Compulsive Disorder- Pre-clinical Phase Drug Overview
7.3 Obsessive-Compulsive Disorder- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Obsessive-Compulsive Disorder- Disease Overview
2.2 Obsessive-Compulsive Disorder- Pipeline Snapshot
2.3 Obsessive-Compulsive Disorder- Pipeline Drugs by Phase
2.4 Obsessive-Compulsive Disorder- Pipeline Drugs by Company
2.5 Obsessive-Compulsive Disorder- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Addex Therapeutics Ltd Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.2 Amorsa Therapeutics Inc Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.3 Biohaven Pharmaceutical Holding Company Ltd Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.4 Omeros Corporation Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.5 Phytecs Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.6 Rugen Therapeutics Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
3.7 Seropeutics LLC Obsessive-Compulsive Disorder Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Obsessive-Compulsive Disorder- Phase 1 Drug Details
4.2 Obsessive-Compulsive Disorder- Phase 1 Drug Overview
4.3 Obsessive-Compulsive Disorder- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Obsessive-Compulsive Disorder- Phase 2 Drug Details
5.2 Obsessive-Compulsive Disorder- Phase 2 Drug Overview
5.3 Obsessive-Compulsive Disorder- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Obsessive-Compulsive Disorder- Phase 3 Drug Details
6.2 Obsessive-Compulsive Disorder- Phase 3 Drug Overview
6.3 Obsessive-Compulsive Disorder- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Obsessive-Compulsive Disorder- Pre-clinical Phase Drug Details
7.2 Obsessive-Compulsive Disorder- Pre-clinical Phase Drug Overview
7.3 Obsessive-Compulsive Disorder- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
